Today: 19 April 2026
Unilever share price today: ULVR slides in London as tariff nerves linger ahead of results
20 January 2026
1 min read

Unilever share price today: ULVR slides in London as tariff nerves linger ahead of results

London, January 20, 2026, 08:47 GMT — Regular session

  • Unilever (ULVR.L) slipped roughly 0.7% early in London, trading near 4,733p
  • Berenberg sticks with its Buy rating on Unilever, maintaining a 5,600p target price
  • Investors are eyeing the Feb. 12 results for clues on volume and margins following the ice cream demerger

Unilever (ULVR.L) shares edged down 0.7% to 4,732.5 pence in early London trade Tuesday. The stock hovered in a tight range, between 4,727p and 4,753p, with about 97,000 shares changing hands. Year to date, the shares are down roughly 2.6%.

European stocks slipped once more, pressured by trade tensions after U.S. President Donald Trump renewed tariff threats against several European nations. By 0803 GMT, the pan-European STOXX 600 had dropped 0.7%, Reuters noted.

Unilever had no clear new driver during the session. The shares moved as usual—anchored as a major defensive consumer stock that tends to follow broader market swings when risk appetite fades.

A broker note brought a company-specific angle. On Monday, Berenberg analyst Fulvio Cazzol reaffirmed a Buy rating, maintaining a target price of 5,600 pence and describing the stock as “attractive.” MarketScreener

Investors are eyeing the calendar closely. Unilever is set to release its fourth-quarter and full-year 2025 results on Feb. 12, with a scheduled appearance at the CAGNY Conference on Feb. 17, according to its investor site.

In a pre-close note dated Jan. 8, Unilever projected 2025 underlying sales growth—excluding currency and M&A effects—between 3% and 5%. The company expects second-half underlying operating margin to hit at least 19.5%. Fourth-quarter underlying volume growth should match or exceed the third quarter’s 1.7%. It also said tariff impacts on profitability were limited and already factored into margin forecasts.

February’s report will be the first to show a full year of figures excluding ice cream, now classified as discontinued following the split. Unilever announced in December that its ice cream division, renamed The Magnum Ice Cream Company, was spun off on Dec. 6. New shares began trading Dec. 8, with a share consolidation happening the next day.

Investors are now digging deeper into the remaining mix, searching for signs that volume can keep climbing even as price gains slow. They’re also looking for evidence that margins stay strong while the group invests in brands and drives productivity savings. Cash flow and any hints on capital returns will draw just as much scrutiny.

February’s numbers will be a clear turning point. Falling short on volumes, weaker margin guidance, or currency headwinds could swiftly change the outlook—even for a company primarily recognized for soap, deodorant, and pantry staples.

For now, macro factors will likely keep dominating the tape. Traders are focused on whether tariff threats turn into actual policy starting Feb. 1 and how that impacts overall risk sentiment. Unilever’s key upcoming events are its Feb. 12 earnings and the CAGNY presentation on Feb. 17.

Stock Market Today

  • How Defensive Stocks Could Boost Your 401(k) This Summer
    April 18, 2026, 10:58 PM EDT. Seasonal stock market trends suggest selling in May, but experts caution against it in 2026. Instead, financial analysts Mark Hulbert and Sam Stovall recommend rotating investments into defensive stocks during the summer months. These stocks, found in sectors like healthcare and consumer staples, are less sensitive to economic swings and provide stable returns. Hulbert advises using ETFs such as Consumer Staples Select Sector SPDR (XLP) and Health Care Select Sector SPDR (XLV) for this strategy. These ETFs offer low fees and exposure to essential goods and services companies, offering potential portfolio stability during typical market volatility in May to October. This approach could make a meaningful difference to your 401(k) performance by balancing growth and risk through seasonal shifts.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Wesfarmers walks away from a $400m Priceline rescue — and now the Infinity pharmacies are up for grabs
Previous Story

Wesfarmers walks away from a $400m Priceline rescue — and now the Infinity pharmacies are up for grabs

Tesco share price edges lower in London after fresh buyback as April results loom
Next Story

Tesco share price edges lower in London after fresh buyback as April results loom

Go toTop